Expert Interview
Discussion on the recent FDA approval of Dupixent (dupilumab) for Chronic Spontaneous Urticaria and its implications for treatment strategies and patient care.
Ticker(s): SNY, REGNInstitution: University of Rochester
- Professor of Dermatology, Professor of Medicine (AIR) and Pathology & Laboratory Medicine at University of Rochester Medical Center.
- Manages 500 patients with atopic dermatitis (60% Pediatric) and 30 patients per month with chronic urticaria.
- Research was instrumental in the development of dupilumab (Dupixent); Lead author of a 2014 NEJM paper that set the stage for the FDA approval of Dupixent.
Roughly how many patients with CSU do you manage monthly?
Added By: dami_adminHow do you see the FDA approval of Dupixent for CSU changing the current treatment landscape for patients who remain symptomatic despite antihistamines?
Added By: dami_adminHow do the efficacy and safety data from the LIBERTY-CUPID trials align with your expectations and real-world experience in treating CSU?
Added By: dami_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
